William Y. Go

16.5k total citations · 3 hit papers
67 papers, 3.6k citations indexed

About

William Y. Go is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, William Y. Go has authored 67 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 21 papers in Immunology and 20 papers in Molecular Biology. Recurrent topics in William Y. Go's work include CAR-T cell therapy research (37 papers), Biosimilars and Bioanalytical Methods (17 papers) and Lymphoma Diagnosis and Treatment (10 papers). William Y. Go is often cited by papers focused on CAR-T cell therapy research (37 papers), Biosimilars and Bioanalytical Methods (17 papers) and Lymphoma Diagnosis and Treatment (10 papers). William Y. Go collaborates with scholars based in United States, France and Spain. William Y. Go's co-authors include Sattva S. Neelapu, Steffan N. Ho, Jeff Wiezorek, J. Randolph Hecht, Lynn Navale, Frederick L. Locke, Umar Farooq, Jason R. Westin, John Kuruvilla and Michael Crump and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

William Y. Go

64 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

2017 1.0k citations Michael Crump, Sattva S. Neelapu et al. Blood profile →
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

2014 478 citations Lee S. Schwartzberg, Fernando Rivera et al. Journal of Clinical Oncology profile →
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

2017 463 citations Frederick L. Locke, Sattva S. Neelapu et al. Molecular Therapy profile →

Peers

Countries citing papers authored by William Y. Go

Since Specialization

Citations

This map shows the geographic impact of William Y. Go's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Y. Go with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Y. Go more than expected).

Fields of papers citing papers by William Y. Go

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Y. Go. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Y. Go. The network helps show where William Y. Go may publish in the future.

Co-authorship network of co-authors of William Y. Go

This figure shows the co-authorship network connecting the top 25 collaborators of William Y. Go. A scholar is included among the top collaborators of William Y. Go based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Y. Go. William Y. Go is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A02 (HLA-A02) loss of heterozygosity (LOH). 2024 ·Journal of Clinical Oncology ·(unknown), Diane M. Simeone, Patrick Grierson, Kedar Kirtane, Maria Pia Morelli, Sandip Pravin Patel, Matthew L. Ulrickson, Saurabh Dahiya, Jong Chul Park, Jennifer M. Specht, Marwan Fakih, (unknown), Jessica Tebbets, John S. Welch, William Y. Go, David G. Maloney, Marcela V. Maus, (unknown), J. Randolph Hecht	0
2	EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A02 loss of heterozygosity (LOH). 2024 ·Journal of Clinical Oncology* ·Salman R. Punekar, J. Randolph Hecht, (unknown), Diane M. Simeone, Oliver Dorigo, Leslie R. Boyd, Kedar Kirtane, Jeffrey D. Ward, Frederick L. Locke, Maria Pia Morelli, Matthew S. Block, Ramez N. Eskander, Wendy J. Langeberg, (unknown), (unknown), William Y. Go, David G. Maloney, Marcela V. Maus, John S. Welch, Julian R. Molina	5
3	Salvianolic acids modulate lifespan and gut microbiota composition in amyloid-β-expressing Drosophila melanogaster 2024 ·World Journal of Microbiology and Biotechnology ·William Y. Go, Intan H. Ishak, Kamarul Zaman Zarkasi, Ghows Azzam	1
4	Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities 2024 ·npj Precision Oncology ·(unknown), (unknown), Qidi Yang, Mario G. Rosasco, John S. Welch, William Y. Go, (unknown), Armen Mardiros, David G. Maloney, Edward B. Garon, Kedar Kirtane, Diane M. Simeone, Julian R. Molina, Ameen A. Salahudeen, Michelle M. Stein, J. Randolph Hecht	5
5	Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy 2020 ·JCI Insight ·Pei-Hsuan Chen, Mikel Lipschitz, Jason L. Weirather, Caron A. Jacobson, Philippe Armand, Kyle Wright, F. Stephen Hodi, Zachary Roberts, Stuart A. Sievers, John M. Rossi, Adrian Bot, William Y. Go, Scott J. Rodig	59
6	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study breakdown → 2017 ·Blood ·Michael Crump, Sattva S. Neelapu, Umar Farooq, Éric Van Den Neste, John Kuruvilla, Jason R. Westin, Brian K. Link, Annette E. Hay, James R. Cerhan, Liting Zhu, Sami Boussetta, Lei Feng, Matthew J. Maurer, Lynn Navale, Jeff Wiezorek, William Y. Go, Christian Gisselbrecht	1042
7	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma breakdown → 2017 ·Molecular Therapy ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Armin Ghobadi, Lihua E. Budde, Adrian Bot, John M. Rossi, Yizhou Jiang, Allen Xue, Meg Elias, Jeff Aycock, Jeff Wiezorek, William Y. Go	463
8	A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1 2016 ·Blood ·Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Tanya Siddiqi, Caron A. Jacobson, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Alex F. Herrera, Ann S. LaCasce, Adrian Bot, John M. Rossi, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go	23
9	ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL) 2016 ·Annals of Oncology ·Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Tanya Siddiqi, Ira Braunschweig, Lazaros J. Lekakis, André Goy, Januario E. Castro, Olalekan O. Oluwole, David B. Miklos, John M. Timmerman, Caron A. Jacobson, Patrick M. Reagan, Ian W. Flinn, Umar Farooq, Patrick J. Stiff, Lynn Navale, Meg Elias, Jeff Wiezorek, William Y. Go	2
10	ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL) 2016 ·Annals of Oncology ·M. Wang, Frederick L. Locke, Tanya Siddiqi, Januario E. Castro, Bijal Shah, (unknown), Lihua E. Budde, Michael Y. Choi, Claudio Anasetti, Richard E. Champlin, Stephen J. Forman, Thomas J. Kipps, Adrian Bot, John M. Rossi, Lynn Navale, Yanfei Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Y. Go	7
11	SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer 2015 ·Clinical Colorectal Cancer ·J. Randolph Hecht, Allen Lee Cohn, Shaker R. Dakhil, Mansoor N. Saleh, Bilal Piperdi, (unknown), Ying Tian, William Y. Go	96
12	Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy 2015 ·Blood ·Arianne Perez, Lynn Navale, John M. Rossi, Yueh-wei Shen, Yizhou Jiang, Marika Sherman, Armen Mardiros, Sean C. Yoder, William Y. Go, Steven A. Rosenberg, Jeff Wiezorek, Margo R. Roberts, David Chang, James N. Kochenderfer, Adrian Bot	3
13	PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer breakdown → 2014 ·Journal of Clinical Oncology ·Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus, Gianpiero Fasola, Jean-Luc Canon, J. Randolph Hecht, Hua Yu, Kelly S. Oliner, William Y. Go	478
14	A Splenic Artery Aneurysm That Mimics a Stromal Tumor and Causes Hematemesis 2010 ·Clinical Gastroenterology and Hepatology ·Raymond S. Tang, (unknown), William Y. Go	1
15	atp2b1a regulates Ca2+ export during differentiation and regeneration of mechanosensory hair cells in zebrafish 2010 ·Cell Calcium ·William Y. Go, Dmitri A. Bessarab, Vladimir Korzh	23
16	Zebrafish transgenic Enhancer TRAP line database (ZETRAP) 2006 ·BMC Developmental Biology ·(unknown), (unknown), (unknown), Alexander Emelyanov, William Y. Go, (unknown), Vladimir Korzh	64
17	Identification of the cytoskeletal regulatory protein α-adducin as a target of T cell receptor signaling 2004 ·Molecular Immunology ·Qing‐Bin Lu, Xuedong Liu, Jason P. Trama, Michelle Roti, William Y. Go, Samuel B. Ho	6
18	The Osmoprotective Function of the NFAT5 Transcription Factor in T Cell Development and Activation 2002 ·The Journal of Immunology ·Jason P. Trama, William Y. Go, Steffan N. Ho	83
19	Optimization and direct comparison of the dimerizer and reverse tet transcriptional control systems 2002 ·The Journal of Gene Medicine ·William Y. Go, Steffan N. Ho	19
20	Quantitative Dynamic Multicompartmental Analysis of Cholecystokinin Receptor Movement in a Living Cell Using Dual Fluorophores and Reconstruction of Confocal Images 1997 ·Analytical Biochemistry ·William Y. Go, Belinda F. Roettger, Eileen L. Holicky, Elizabeth M. Hadac, Laurence J. Miller	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact